GlassScriptPhysician profile
Jane C Reed
NPI 1306824701
$1,158.00
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $711 · 2021: $40.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $601.00 | 2020 | |
| Astellas Pharma US INC | $162.09 | 2019-2020 | |
| Abbvie INC. | $156.63 | 2019-2021 | |
| Hologic Sales and Service, LLC | $52.65 | 2019-2020 | |
| Coloplast Corp | $43.84 | 2019 | |
| Therapeuticsmd, INC. | $37.04 | 2019 | |
| Duchesnay USA Incorporated | $21.34 | 2019 | |
| Aspira Women'S Health INC | $19.15 | 2020 | |
| Amag Pharmaceuticals, INC. | $18.26 | 2019 | |
| Roche Diagnostics Corporation | $16.27 | 2019 | |
| Merck Sharp & Dohme LLC | $16.20 | 2019 | |
| Avanos Medical | $13.53 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.